Glenmark Pharmaceuticals Limited · NSE:GLENMARK
Glenmark Pharmaceuticals — Q3 FY2023 Earnings Presentation
22 slides from Glenmark Pharmaceuticals's earnings presentation, Feb 10, 2023
Slide 1: Investor Presentation – Q3 FY23
Presentation Heading or Sub Heading Glenmark Pharmaceuticals Ltd. Investor Presentation – Q3 FY23 10 February 2023
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Glenmark Pharmaceuticals Ltd. The information, statements and analysis made in this presentation describing Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. These statements are based on current expec
Slide 3: Glenmark’s vision has guided its journey over the last two decades
Glenmark’s vision has guided its journey over the last two decades Glenmark Group, today Leading Integrated Research-led Global Consolidated revenues in FY22: End-to-end R&D capabilities: API, Initiated NME research in 2002; Global diversified formulations ₹ 123,049 mn generic formulations (conventi
Slide 4: Strategic restructuring for sharper focus on our three businesses
Strategic restructuring for sharper focus on our three businesses Separate board Independent Global presence of directors management team & operations Primarily focused on building a global formulation business with branded, generics, and OTC segments in therapy areas of Dermatology, Respiratory and
Slide 5: Committed to Sustainability across all our operations globally
Committed to Sustainability across all our operations globally Environmental Social Governance Become carbon neutral by 2030* 16 global safety programs by 2023 Maintain an ethical business culture to Achieve water neutral operations by Aspire to impact 3 million lives by 2025 drive robust governance
Slide 6: Q3 and 9M FY23 Snapshot
Q3 and 9M FY23 Snapshot • Q3 FY23 Revenues from Operations at Rs. 34,639 Mn with a growth of 9.2% YoY • Q3 FY23 EBITDA of Rs. 6,202 Mn with EBITDA margin of 17.9% • Q3 FY23 Reported PAT of Rs. 2,908 Mn Q3 FY23 “We had yet another quarter with a strong performance led • Consolidated Revenue of Rs. 34
Slide 7: Consolidated revenues from operations
Consolidated revenues from operations Second Quarter ended Third Quarter ended December 31 September 30 YoY Growth QoQ Growth Rs Mn FY 2022-23 FY 2021-22 FY 2022-23 (%) (%) India 10,745 10,069 6.7% 10,916 -1.6% North America 8,373 7,567 10.6% 7,533 11.1% Europe 4,932 3,807 29.5% 3,785 30.3% Rest of
Slide 8: Consolidated revenues from operations
Consolidated revenues from operations Nine Months ended December 31 YoY Growth Rs Mn FY 2022-23 FY 2021-22 (%) India 32,014 32,008 0.0% North America 22,534 22,988 -2.0% Europe 12,016 10,249 17.2% 1 Rest of the World 16,921 16,194 4.5% API 10,751 9,426 14.1% Total 94,236 90,865 3.7% Other Revenue 1,
Slide 9: Revenue distribution by key geographies
Revenue distribution by key geographies 6% 5% 11% 1% 10% 11% 32% 32% 31% 19% 17% Q3 FY22 18% Q2 FY23 Q3 FY23 12% 14% 11% 24% 22% 24% India Europe API North America ROW Other Revenue 9
Slide 10: Revenue distribution by key geographies
Revenue distribution by key geographies 2% 2% 10% 11% 34% 33% 17% 18% 9M FY22 9M FY23 11% 12% 25% 23% India Europe API North America ROW Other Revenue 10
Slide 11: P&L highlights
P&L highlights Rs. Mn Q3 FY23 Q3 FY22 %YoY Q2 FY23 %QoQ Revenues from Operations 34,639 31,734 9.2% 33,752 2.6% EBITDA 6,202 6,932 -10.5% 6,216 -0.2% EBITDA margin (%) 17.9% 21.8% 18.4% Other Income (exp) 764 139 974 Exceptional gain (loss) 339 -1,784 0 Profit Before Tax (PBT) 4,710 3,430 37.3% 4,80
Slide 12: India Formulations
9M FY23 33% India Formulations YoY: 6.7% Revenue (INR Mn) QoQ: -1.6% Q3 FY23 growth of 11% Ranked 2nd in 10,745 10,916 as per IQVIA data 10,069 Respiratory for Q3 FY23 Key Highlights • Glenmark’s India business is ranked 14th1 with a market share of 2.19% Q3 FY23 Q3 FY22 Q2 FY23 • Cardiac segment ma
Slide 13: North America Formulations
9M FY23 North America Formulations 23% YoY: 10.6% Revenue (INR Mn) QoQ: 11.1% Launched 3 new QoQ growth of 11% 8,373 products in Q3 7,567 7,533 Key Highlights Q3 FY23 Q3 FY22 Q2 FY23 • Received final approval for Nicardipine Hydrochloride Capsules, final approval and launch of Sodium Phenylbutyrate
Slide 14: Europe
9M FY23 Europe 12% YoY: 29.5% Revenue (INR Mn) QoQ: 30.3% Ryaltris® and Salmex® / Strong YoY and QoQ Asthmex® gain market growth in region 4,932 share across CEE 3,807 3,785 Key Highlights Q3 FY23 Q3 FY22 Q2 FY23 • Growth driven by markets in both regions of Western Europe (WEU) and Central & Easter
Slide 15: ROW (Asia, MEA, LATAM and RCIS regions)
9M FY23 18% ROW (Asia, MEA, LATAM and RCIS regions) YoY: 22.3% Revenue (INR Mn) QoQ: 6.3% Ryaltris key growth driver 6,541 22% growth YoY 6,154 across major markets 5,348 Key Highlights RCIS • Secondary sales growth of 26% in value and 3% in units in Q3 FY23 (vs same period last year) • Ryaltris gai
Slide 16: API business (Glenmark Life Sciences)
11% 9M FY23 API business (Glenmark Life Sciences) YoY: 23.9% Revenue – External Sales (INR Mn) QoQ: 0.3% Multiple projects 76.5% contribution from 3,756 3,744 completed / ongoing for regulated markets 3,032 capacity expansion Key Highlights Q3 FY23 Q3 FY22 Q2 FY23 • Consolidated sales of Rs. 5,407 M
Slide 17: Respiratory Strategy – Creating Global Scale
Respiratory Strategy – Creating Global Scale • As of the end of Q3, marketing applications submitted in 58 countries across the world and commercialized in 23 markets, including major markets like the US, Europe (UK and 10 other markets across the EU), Australia, Russia, South Korea and South Africa
Slide 18: Innovative R&D Pipeline
Innovative R&D Pipeline • Oncology pipeline asset being developed as an orally administered IO-adjuvant treatment for patients with solid tumors. A Phase 1 dose escalation study is ongoing in India. GRC 54276 • Successful recruitment of patients in Cohort 3 was completed in Q3 FY23. No dose limiting
Slide 19: Ichnos Sciences is a Clinical-Stage Biotechnology Company at the Forefront of Innovation in Oncology
Ichnos Sciences is a Clinical-Stage Biotechnology Company at the Forefront of Innovation in Oncology • Global footprint: U.S. and Switzerland Fully Integrated • Fully owned by Glenmark, with plans to expand the investor base in the future Biotech • Accomplished management team with proven track reco
Slide 20: Ichnos is Advancing a Differentiated Pipeline with Potential First – and Best-in-Class Assets
Ichnos is Advancing a Differentiated Pipeline with Potential First – and Best-in-Class Assets Ichnos Oncology Pipeline - First Wave Focuses on T-Cell Ichnos to Out-License Assets in Autoimmune (AI) Disease Engagers and Macrophage Modulators Molecule Molecule Potential Phase/Status Lead Indication Me
Slide 21: Key Objectives of Financial Year 2023
Key Objectives of Financial Year 2023 1 Revenue growth of 6-8% during the year 2 Sustain EBITDA margin performance at similar levels of FY22 3 Strategic priority to enhance free cash generation for further debt reduction 4 Capex of Rs. 7-8 Bn 5 Continue discussions with potential partners for out-li
Slide 22: Thank You
Thank You https://glenmarkpharma.com/
Glenmark Pharmaceuticals — Q3 FY2023 Earnings Presentation on 6ix